title: Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration.
abstract: This retrospective chart review describes the efficacy and safety of long-term administration of intravenous alpha1-antitrypsin (AAT) in 14 patients with hereditary AAT deficiency and COPD. During the 12- to 48-month observation period, 12 to 14 patients had stabilization of functional status; 4 patients had reductions in hospitalizations. Thirteen of 14 patients had no decline in pulmonary function. Three patients had self-limited adverse reactions to the AAT with one patient requiring a brief hospitalization.
authors.affiliation: Department of Pulmonary and Critical Care Medicine, Oregon Health Sciences University, Portland.
authors.forename: A F
authors.initials: AF
authors.lastname: Barker
authors.forename: F
authors.initials: F
authors.lastname: Siemsen
authors.forename: D
authors.initials: D
authors.lastname: Pasley
authors.forename: R
authors.initials: R
authors.lastname: D'Silva
authors.forename: A S
authors.initials: AS
authors.lastname: Buist
mesh_terms: D000328:Adult; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007262:Infusions, Intravenous; D008173:Lung Diseases, Obstructive / Q000150:complications* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D012189:Retrospective Studies; D014797:Vital Capacity; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage* / Q000009:adverse effects; D019896:alpha 1-Antitrypsin Deficiency
chemical_list: D000515:alpha 1-Antitrypsin